Assessing Honey Jell® as a Treatment for Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Radiotherapy: Double Blind Phase III Clinical Trial Honey Jell for Reducing CRF

Hossein Rezaeizadeh (1), Masoumeh Najafi (2), Farnaz Amouzegar Hashemi (3), Fatemeh Jafari (4), Amin Jahanbakhshi (5), Peiman Haddad (6), Mahdi Aghili (7), Bita Kalaghchi (8)
(1) School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran, Iran, Islamic Republic of,
(2) Skull Base Research Center, Neurosurgery Department, Iran University of Medical Sciences, Iran, Islamic Republic of,
(3) Radiation Oncology Research Center, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, Iran, Islamic Republic of,
(4) Radiation Oncology Research Center, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, Iran, Islamic Republic of,
(5) Skull Base Research Center, Neurosurgery Department, Iran University of Medical Sciences, Iran, Islamic Republic of,
(6) Skull Base Research Center, Neurosurgery Department, Iran University of Medical Sciences, Iran, Islamic Republic of,
(7) Radiation Oncology Research Center, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, Iran, Islamic Republic of,
(8) Radiation Oncology Research Center, Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, Iran, Islamic Republic of

Abstract

Background: Cancer-Related Fatigue (CRF) is one of the most common complaints among cancer patients, which is experienced by 50-90% of them. It can affect several physical, emotional, and social aspects of cancer patients' lives and reduce their quality of life. In recent decades, the number of studies has increased in this regard, and several different ways for CRF management have been introduced. We aimed to assess the effect of Honey Jell ® on reducing cancer-related fatigue among breast cancer patients undergoing cancer treatment. 


Methods: The current study was a 9-week, double-blind, randomized phase III clinical trial, which was carried out on 40 breast cancer patients at the Cancer Institute of Iran. The participants were randomly assigned to two groups by the Balanced-Block Randomization method. The study group received Honey Jell ® (natural product based on honey, royal jelly, and extract of Ziziphus zizyphus) while we used ordinary honey as a placebo for the control group. We assessed CRF at baseline, 2 and 4 weeks after the start of the study and four weeks after finishing the intervention using three different approaches. The mean score of fatigue was compared between the study groups during the study period using the T-test. 


Results: Mean of fatigue score for intervention and control cases was 39.80 (±9.6) and 38.4 (±11.1) at the baseline (P-value= 0.698). The figure reduced to 31.55 (±6.08) for the intervention group in the 2nd week, while for controls, it was 35.55 (±8.2) (P=0.041). The mean score of fatigue continuously reduced to 30.65 (±6.86) in the fourth week in the intervention cases, which was considerably lower than the figure for controls (36.05±5.20) (P=0.024). The mean score of CRF in the intervention group increased 31.80 (±6.91) four weeks after the end of the study, while it was almost unchanged for controls (36.64±6.13) and the observed difference was not statistically significant (P=0.148). 


Conclusion: Honey Jell ® could be considered as an effective treatment to alleviate cancer-related fatigue. However, more studies are required in this regard. 

Full text article

Generated from XML file

References

Gupta D, Lis CG, Grutsch JF. The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer. Journal of Pain and Symptom Management. 2007;34:40–7. doi: 10.1016/j.jpainsymman.2006.10.012.

Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Annals of Oncology. 2000;11:971–5. doi: 10.1023/A:1008318932641.

Jereczek-Fossa BA, Santoro L, Alterio D, Franchi B, Fiore MR, Fossati P, et al. Fatigue During Head-And-Neck Radiotherapy: Prospective Study on 117 Consecutive Patients. International Journal of Radiation Oncology*Biology*Physics. 2007;68:403–15. doi: 10.1016/j.ijrobp.2007.01.024.

Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells. New England Journal of Medicine. 1988;318:1557–63. doi: 10.1056/nejm198806163182401.

Campos MPO, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: A practical review. Annals of Oncology. 2011:1273–9. doi: 10.1093/annonc/mdq458.

Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition - PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/9253778/ [accessed March 17, 2021].

Lis CG, Rodeghier M, Grutsch JF, Gupta D. Distribution and determinants of patient satisfaction in oncology with a focus on health related quality of life. BMC Health Services Research. 2009;9. doi: 10.1186/1472-6963-9-190.

Horneber M, Fischer I, Dimeo F, Rüffer JU, Weis J. Tumor-assoziierte Fatigue: Epidemiologie, pathogenese, diagnostik und therapie. Deutsches Arzteblatt International. 2012;109:161–72. doi: 10.3238/arztebl.2012.0161.

Wang XS. Pathophysiology of cancer-related fatigue. Clinical Journal of Oncology Nursing. 2008;12:11–20. doi: 10.1188/08.CJON.S2.11-20.

Hofman M, Ryan JL, Figueroa‐Moseley CD, Jean‐Pierre P, Morrow GR. Cancer‐Related Fatigue: The Scale of the Problem. The Oncologist. 2007;12:4–10. doi: 10.1634/theoncologist.12-s1-4.

Passos CS, Ribeiro Sady ER, Passos Neves RV, Piovezani Carvalho BE, Santos Rodrigues Costa T, Haro AS, et al. Cancer and radiotherapy-related fatigue: implications and therapies integratives. Journal of Medical Oncology and Therapeutics. 2018;03. doi: 10.35841/medical-oncology.3.1.9-14.

Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: A randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Supportive Care in Cancer. 2010;18:179–87. doi: 10.1007/s00520-009-0642-2.

Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05c7 trial. Journal of Clinical Oncology. 2010;28:3673–9. doi: 10.1200/JCO.2010.28.1444.

Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, et al. Effect of paroxetine hydrochloride (Paxil®) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment. 2005;89:243–9. doi: 10.1007/s10549-004-2175-1.

Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, Yoon SW. Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Integrative Cancer Therapies. 2010;9:331–8. doi: 10.1177/1534735410383170.

Mofid B, Rezaeizadeh H, Termos A, Rakhsha A, Rezazadeh Mafi A, Taheripanah T. Effect of Processed Honey and Royal Jelly on Cancer-Related Fatigue: A Double-Blind Randomized Clinical Trial. Electron Physician. 2016;8:2475–82. doi: 10.19082/2475.

Kamakura M, Mitani N, Fukuda T, Fukushima M. Antifatigue effect of fresh royal jelly in mice. Journal of Nutritional Science and Vitaminology. 2001;47:394–401. doi: 10.3177/jnsv.47.394.

Pourahmad M, Sobhanian S. Effect of Honey on the Common Cold. Archives of Medical Research. 2009:224–5. doi: 10.1016/j.arcmed.2009.01.001.

Nakaya M, Onda H, Sasaki K, Yukiyoshi A, Tachibana H, Yamada K. Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. Bioscience, Biotechnology and Biochemistry. 2007;71:253–5. doi: 10.1271/bbb.60453.

Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, et al. Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxidative Medicine and Cellular Longevity. 2011;2011. doi: 10.1155/2011/981793.

Fauzi AN, Norazmi MN, Yaacob NS. Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food and Chemical Toxicology. 2011;49:871–8. doi: 10.1016/j.fct.2010.12.010.

Erem C, Deger O, Ovali E, Barlak Y. The effects of royal jelly on autoimmunity in Graves’ disease. Endocrine. 2006;30:175–83. doi: 10.1385/ENDO:30:2:175.

Authors

Hossein Rezaeizadeh
Masoumeh Najafi
Farnaz Amouzegar Hashemi
Fatemeh Jafari
Amin Jahanbakhshi
Peiman Haddad
Mahdi Aghili
Bita Kalaghchi
bitakalaghchi@gmail.com (Primary Contact)
1.
Rezaeizadeh H, Najafi M, Amouzegar Hashemi F, Jafari F, Jahanbakhshi A, Haddad P, Aghili M, Kalaghchi B. Assessing Honey Jell® as a Treatment for Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Radiotherapy: Double Blind Phase III Clinical Trial: Honey Jell for Reducing CRF. Arch Breast Cancer [Internet]. 2022 Mar. 31 [cited 2024 Nov. 4];9(3):358-63. Available from: https://archbreastcancer.com/index.php/abc/article/view/508

Article Details

Most read articles by the same author(s)

1 2 > >>